Navigation Links
Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
Date:12/11/2012

ATLANTA, Dec. 11, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced follow-up findings from an ongoing, open-label, Phase 2, single-agent study suggesting that in patients with relapsed or refractory mantle cell lymphoma (MCL), both those who were bortezomib-naive and bortezomib-exposed, the investigational oral agent ibrutinib (PCI-32765) resulted in high and durable responses and was generally well tolerated. In the study, 111 patients received ibrutinib and 110 were evaluable for efficacy. The median follow-up time was 9.2 months, with a range of time to response to treatment of 1.4 to 16.4 months.

The results were presented by lead investigator Michael L. Wang, M.D., associate professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, at the 54th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Ga. The study showed an overall response rate (ORR) of 68 percent, including a complete response (CR) of 22 percent and a partial response (PR) of 46 percent with a median progression free survival (PFS) estimated at 13.9 months. Results were similar between the bortezomib-naive and bortezomib-exposed patients.

Long-term follow up of the initial 51 patients enrolled in this study that were presented last year at ASH shows there was an incremental improvement in the response rate over time. The ORR increased for this patient subset from 69 percent in 2011 to an ORR of 75 percent in 2012, with the CR increasing from 16 percent to 39 percent over the same period.

"Now with a larger number of patients studied, we see the overall response rate remains durable and the safety profile continues to appear manageable," said Dr. Wang. "In addition, what is particularly encouraging is that with longer follow-up there is an incremental increase in the number of patients who achiev
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
2. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
3. VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
6. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
7. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
8. Perrigo Company Will Release Third Quarter Fiscal 2012 Results On May 8, 2012
9. Genomic Health to Announce First Quarter 2012 Financial Results and Host Conference Call on Wednesday, May 2, 2012
10. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , August 28, 2015 ... Market by Tumor (Breast, Lung, Prostate) Type (Protein & ... (Diagnostic, Drug Discovery, Prognostic) & Geography - Global Forecast ... is expected to reach around 17,689.0 Million USD by ... period of 2015 to 2020. Browse ...
(Date:8/28/2015)... Utah , Aug. 28, 2015  Today, in ... Prevention,s (CDC) Contact Lens Health Week, 1-800 Contacts is ... has found that contact lens wearers who do not ... greatest risk for eye infections. Most ... their lenses, but a clean lens case is sometimes ...
(Date:8/28/2015)... , Aug. 28, 2015 ... addition of the "Investigation Report on China,s Ranibizumab ... Developed by Novartis, ranibizumab was approved by CFDA to ... Currently, only Lucentis, a product of Novartis, is available ... the first self- developed drug for the treatment of ...
Breaking Medicine Technology:Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 51-800 Contacts Shares Tips on How to Clean Lens Cases 2Investigation Report on China's Ranibizumab Market, 2012-2019 2
... DIEGO, Nov. 24 Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ... Annual Piper Jaffray Healthcare Conference on Tuesday, December 1, 2009 ... is being held at The New York Palace Hotel. ... will provide an overview of Anadys and its clinical development ...
... , POTOMAC, Md., Nov. 24 In ... has added Philadelphia jurors to her Thanksgiving gratitude list. ... I am so thankful to them," she said of Monday,s ... , Wisneski is among 12,000 women nationwide who have sued ...
Cached Medicine Technology:Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Maryland Woman Thankful for Wyeth Verdicts 2
(Date:8/29/2015)... (PRWEB) , ... August 30, 2015 , ... Rio ... O’Shea to serve as the college’s Vice President of Strategic Initiatives and Information Services. ... eager to help the college expand its reach and impact through innovative technologies and ...
(Date:8/29/2015)... PITTSBURGH, PA (PRWEB) , ... August 29, 2015 ... ... 1996," said one of two inventors from Miller Place, N.Y. "I specialize in ... pain and discomfort. In addition, it can be used for additional muscle dysfunction ...
(Date:8/29/2015)... ... , ... Brands like Toppik , Eau Thermale Avene and Bliss are ... threshold of $49.00 was required to qualify for free standard shipping,” said Jennifer Ramirez, ... for customers regardless of the item’s selling price.” , With competitive pricing in the ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain ... stretching, soft tissue manipulation. Platelet rich plasma injections also have mixed results. ... improve treatment outcomes. This localized treatment seems to address the symptoms and ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... center management, Decatur County Memorial Hospital recently transitioned management companies to partner with ... Center Management for their outpatient wound center. , Transitioning wound care management ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
... of Experimental Medicine -, - Findings Underscore Versatility ... Antagonists as Possible ... TorreyPines Therapeutics, Inc.,(Nasdaq: TPTX ) today announced ... Hopkins University (JHU) for intellectual property,related to the novel ...
... Blue Cross and Blue Shield of,Florida ... been appointed Market,President - West Florida, effective ... (Logo: http://www.newscom.com/cgi-bin/prnh/20000427/BLUELOGOA ), ... has served in a number of leadership ...
... May 1 Cadient Group, the,premier strategic interactive ... has appointed Barbara Dowling as Senior Vice,President, Customer ... on both the client and agency side, Barb ... to address business critical,issues. In this role, Dowling ...
... 1 Nu Skin Enterprises, Inc.,(NYSE: NUS ... a 9,percent improvement over the prior-year period. Earnings ... 31 percent increase compared to the same,quarter of ... 6 percent,by foreign currency fluctuations. Quarterly earnings per ...
... Calif., May 1 Cardiogenesis,Corporation (Pink Sheets: CGCP), ... first quarter ended March 31, 2008 prior to ... also said that President Richard P.,Lanigan and Senior ... will host an investor conference call that day ...
... Performs with Peerless Safety and Proven Efficacy in all Four ... Chambers of the Heart, Stereotaxis to Introduce ... ... May 1 Stereotaxis, Inc. (Nasdaq:,STXS), announced today that approximately 15,000 procedures have been,performed ...
Cached Medicine News:Health News:TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack 2Health News:TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack 3Health News:TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack 4Health News:David Pizzo Appointed Blue Cross and Blue Shield of Florida Market President - West Florida 2Health News:Cadient Group Appoints Barbara Dowling to Senior Vice President Customer Engagements 2Health News:Nu Skin Enterprises Reports First-Quarter 2008 Results 2Health News:Nu Skin Enterprises Reports First-Quarter 2008 Results 3Health News:Nu Skin Enterprises Reports First-Quarter 2008 Results 4Health News:Nu Skin Enterprises Reports First-Quarter 2008 Results 5Health News:Nu Skin Enterprises Reports First-Quarter 2008 Results 6Health News:Nu Skin Enterprises Reports First-Quarter 2008 Results 7Health News:Nu Skin Enterprises Reports First-Quarter 2008 Results 8Health News:Nu Skin Enterprises Reports First-Quarter 2008 Results 9Health News:Nu Skin Enterprises Reports First-Quarter 2008 Results 10Health News:Stereotaxis Niobe Magnetic Navigation Systems Perform Approximately 15,000 Cases 2Health News:Stereotaxis Niobe Magnetic Navigation Systems Perform Approximately 15,000 Cases 3Health News:Stereotaxis Niobe Magnetic Navigation Systems Perform Approximately 15,000 Cases 4
An indirect immunofluorescence (IFA) antibody test for the detection and semiquantitation of anti-glomerular basement membrane (GBM) antibodies in human serum. Slide Detail: 6-well Monkey Kidney Subs...
An enzyme linked immunosorbant assay (ELISA) for the detection and quantitation of Rheumatoid Factor (RF) IgA isotype in human serum....
An enzyme linked immunoassay (ELISA) for the detection and semiquantitation of IgG, IgA or IgM anticardiolipin antibodies, as an aid in assessing the risk of thrombosis in individuals with Systemic L...
The ImagingPlanet 70 mm surgical microscope video adapter: Superior optical quality and precise engineering make this 70 mm focal length adapter an excellent decision for use with your Leica surgica...
Medicine Products: